Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 518

1.

Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group.

Kreissl S, Goergen H, Müller H, Meissner J, Mehnert A, Bürkle C, Fuchs M, Engert A, Behringer K, Borchmann P; German Hodgkin Study Group.

Leuk Lymphoma. 2018 Dec 3:1-10. doi: 10.1080/10428194.2018.1540781. [Epub ahead of print]

PMID:
30507313
2.

Phase I Study of Domatinostat (4SC-202), a class I Histone Deacetylase Inhibitor in Patients with Advanced Hematological Malignancies.

von Tresckow B, Sayehli C, Aulitzky WE, Goebeler ME, Schwab M, Braz E, Krauss B, Krauss R, Hermann F, Bartz R, Engert A.

Eur J Haematol. 2018 Oct 22. doi: 10.1111/ejh.13188. [Epub ahead of print]

PMID:
30347469
3.

Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.

von Tresckow B, Kreissl S, Goergen H, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group.

Lancet Haematol. 2018 Oct;5(10):e462-e473. doi: 10.1016/S2352-3026(18)30140-6.

PMID:
30290903
4.

Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma.

Sud A, Thomsen H, Orlando G, Försti A, Law PJ, Broderick P, Cooke R, Hariri F, Pastinen T, Easton DF, Pharoah PDP, Dunning AM, Peto J, Canzian F, Eeles R, Kote-Jarai Z, Muir K, Pashayan N, Campa D; PRACTICAL Consortium, Hoffmann P, Nöthen MM, Jöckel KH, von Strandmann EP, Swerdlow AJ, Engert A, Orr N, Hemminki K, Houlston RS.

Blood. 2018 Nov 8;132(19):2040-2052. doi: 10.1182/blood-2018-06-855296. Epub 2018 Sep 7.

PMID:
30194254
5.

Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.

Walewski J, Hellmann A, Siritanaratkul N, Ozsan GH, Ozcan M, Chuncharunee S, Goh AS, Jurczak W, Koren J, Paszkiewicz-Kozik E, Wang B, Singh S, Huebner D, Engert A, von Tresckow B.

Br J Haematol. 2018 Nov;183(3):400-410. doi: 10.1111/bjh.15539. Epub 2018 Aug 30.

PMID:
30168134
6.

Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma.

Kobe C, Goergen H, Baues C, Kuhnert G, Voltin CA, Zijlstra J, Hoekstra O, Mettler J, Drzezga A, Engert A, Borchmann P, Dietlein M.

Blood. 2018 Nov 22;132(21):2273-2279. doi: 10.1182/blood-2018-05-852129. Epub 2018 Aug 30.

PMID:
30166329
7.

Hodgkin Lymphoma in Adults.

Bröckelmann PJ, Eichenauer DA, Jakob T, Follmann M, Engert A, Skoetz N.

Dtsch Arztebl Int. 2018 Aug 6;115(31-32):535-540. doi: 10.3238/arztebl.2018.0535.

8.

Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG).

Borchmann S, Müller H, Haverkamp H, Baues C, Marková J, Hüttmann A, Glunz A, Fuchs M, Borchmann P, Engert A.

Leukemia. 2018 Aug 21. doi: 10.1038/s41375-018-0240-8. [Epub ahead of print]

PMID:
30131583
9.

Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment.

Sasse S, Reddemann K, Diepstra A, Oschlies I, Schnitter A, Borchmann S, Engert A, Borchmann P, Klapper W.

Haematologica. 2018 Aug 3. pii: haematol.2018.196279. doi: 10.3324/haematol.2018.196279. [Epub ahead of print] No abstract available.

10.

Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.

Eichenauer DA, Plütschow A, Schröder L, Fuchs M, Böll B, von Tresckow B, Diehl V, Borchmann P, Engert A.

Blood. 2018 Oct 4;132(14):1519-1525. doi: 10.1182/blood-2018-02-836437. Epub 2018 Jul 31.

PMID:
30064977
11.

Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18.

Voltin CA, Goergen H, Baues C, Fuchs M, Mettler J, Kreissl S, Oertl J, Klaeser B, Moccia A, Drzezga A, Engert A, Borchmann P, Dietlein M, Kobe C.

Ann Oncol. 2018 Sep 1;29(9):1926-1931. doi: 10.1093/annonc/mdy250.

PMID:
30010775
12.

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).

Goldkuhle M, Dimaki M, Gartlehner G, Monsef I, Dahm P, Glossmann JP, Engert A, von Tresckow B, Skoetz N.

Cochrane Database Syst Rev. 2018 Jul 12;7:CD012556. doi: 10.1002/14651858.CD012556.pub2. Review.

PMID:
30001476
13.

Hodgkin lymphoma in elderly patients.

Borchmann S, Engert A, Böll B.

Curr Opin Oncol. 2018 Sep;30(5):308-316. doi: 10.1097/CCO.0000000000000464.

PMID:
29994901
14.

Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group.

Sasse S, Goergen H, Plütschow A, Böll B, Eichenauer DA, Fuchs M, Behringer K, Zijlstra JM, Greil R, Markova J, Topp MS, Meissner J, Neubauer A, Baues C, Engert A, Borchmann P, von Tresckow B.

J Clin Oncol. 2018 Sep 1;36(25):2603-2611. doi: 10.1200/JCO.2018.78.7192. Epub 2018 Jul 10.

PMID:
29989855
15.
16.

Hodgkin Lymphoma-Derived Extracellular Vesicles Change the Secretome of Fibroblasts Toward a CAF Phenotype.

Dörsam B, Bösl T, Reiners KS, Barnert S, Schubert R, Shatnyeva O, Zigrino P, Engert A, Hansen HP, von Strandmann EP.

Front Immunol. 2018 Jun 18;9:1358. doi: 10.3389/fimmu.2018.01358. eCollection 2018.

17.

Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma.

Mettler J, Müller H, Voltin CA, Baues C, Klaeser B, Moccia A, Borchmann P, Engert A, Kuhnert G, Drzezga AE, Dietlein M, Kobe C.

J Nucl Med. 2018 Jun 7. pii: jnumed.118.210047. doi: 10.2967/jnumed.118.210047. [Epub ahead of print]

PMID:
29880508
18.

Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Eichenauer DA, Aleman BMP, André M, Federico M, Hutchings M, Illidge T, Engert A, Ladetto M; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv19-iv29. doi: 10.1093/annonc/mdy080. No abstract available.

PMID:
29796651
19.

Whole genome sequencing reveals DICER1 as a candidate predisposing gene in familial Hodgkin lymphoma.

Bandapalli OR, Paramasivam N, Giangiobbe S, Kumar A, Benisch W, Engert A, Witzens-Harig M, Schlesner M, Hemminki K, Försti A.

Int J Cancer. 2018 Oct 15;143(8):2076-2078. doi: 10.1002/ijc.31576. Epub 2018 Jul 26. No abstract available.

PMID:
29708584
20.

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM.

J Clin Oncol. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27.

21.

Balancing risk and benefit in early-stage classical Hodgkin lymphoma.

Bröckelmann PJ, Sasse S, Engert A.

Blood. 2018 Apr 12;131(15):1666-1678. doi: 10.1182/blood-2017-10-772665. Epub 2018 Mar 2. Review.

PMID:
29500174
22.

Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.

Eichenauer DA, Engert A.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):324-328. doi: 10.1182/asheducation-2017.1.324. Review.

PMID:
29222274
23.

Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility.

Sud A, Thomsen H, Law PJ, Försti A, Filho MIDS, Holroyd A, Broderick P, Orlando G, Lenive O, Wright L, Cooke R, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Eeles R, Kote-Jarai Z, Muir K, Pashayan N; PRACTICAL consortium, Hoffmann P, Nöthen MM, Jöckel KH, Strandmann EPV, Lightfoot T, Kane E, Roman E, Lake A, Montgomery D, Jarrett RF, Swerdlow AJ, Engert A, Orr N, Hemminki K, Houlston RS.

Nat Commun. 2017 Dec 1;8(1):1892. doi: 10.1038/s41467-017-00320-1.

24.

Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.

Eichenauer DA, Plütschow A, Kreissl S, Sökler M, Hellmuth JC, Meissner J, Mathas S, Topp MS, Behringer K, Klapper W, Kuhnert G, Dietlein M, Kobe C, Fuchs M, Diehl V, Engert A, Borchmann P.

Lancet Oncol. 2017 Dec;18(12):1680-1687. doi: 10.1016/S1470-2045(17)30696-4. Epub 2017 Nov 10.

PMID:
29133014
25.

Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitude.

Borchmann S, Müller H, Engert A.

Sci Rep. 2017 Nov 2;7(1):14903. doi: 10.1038/s41598-017-14805-y.

26.

Checkpoint Inhibition in Hodgkin Lymphoma - a Review.

Bröckelmann PJ, Engert A.

Oncol Res Treat. 2017;40(11):654-660. doi: 10.1159/000481800. Epub 2017 Oct 20. Review.

27.

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.

Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A.

Lancet. 2018 Dec 23;390(10114):2790-2802. doi: 10.1016/S0140-6736(17)32134-7. Epub 2017 Oct 20.

PMID:
29061295
28.

Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials.

Eichenauer DA, Becker I, Monsef I, Chadwick N, de Sanctis V, Federico M, Fortpied C, Gianni AM, Henry-Amar M, Hoskin P, Johnson P, Luminari S, Bellei M, Pulsoni A, Sydes MR, Valagussa P, Viviani S, Engert A, Franklin J.

Haematologica. 2017 Oct;102(10):1748-1757. doi: 10.3324/haematol.2017.167478. Epub 2017 Sep 14. Review.

29.

Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.

Franklin J, Eichenauer DA, Becker I, Monsef I, Engert A.

Cochrane Database Syst Rev. 2017 Sep 13;9:CD008814. doi: 10.1002/14651858.CD008814.pub2. Review.

PMID:
28901021
30.

R-CHOP in NLPHL: who should receive it?

Eichenauer DA, Engert A.

Blood. 2017 Jul 27;130(4):387-388. doi: 10.1182/blood-2017-05-786301. No abstract available.

31.

The genetics of Hodgkin lymphoma: an overview and clinical implications.

Borchmann S, Engert A.

Curr Opin Oncol. 2017 Sep;29(5):307-314. doi: 10.1097/CCO.0000000000000396. Review.

PMID:
28697001
32.

[Recovery of paraffin blocks and central archiving : Experiences of the Kiel lymph node registry and the German study group for Hodgkin lymphoma].

Čavčić M, Oschlies I, Fuchs M, Engert A, Klapper W.

Pathologe. 2017 Nov;38(6):529-534. doi: 10.1007/s00292-017-0321-x. German.

PMID:
28676898
33.

The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.

Eichenauer DA, Engert A.

Expert Rev Hematol. 2017 Sep;10(9):775-782. doi: 10.1080/17474086.2017.1350167. Epub 2017 Jul 10. Review.

PMID:
28665214
34.

Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.

Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B.

Cochrane Database Syst Rev. 2017 May 25;5:CD007941. doi: 10.1002/14651858.CD007941.pub3. Review.

PMID:
28541603
35.

Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.

Blank O, von Tresckow B, Monsef I, Specht L, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2017 Apr 27;4:CD007110. doi: 10.1002/14651858.CD007110.pub3. Review.

PMID:
28447341
36.

Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition.

Hude I, Sasse S, Bröckelmann PJ, von Tresckow B, Momotow J, Engert A, Borchmann S.

Br J Haematol. 2018 Jun;181(6):837-840. doi: 10.1111/bjh.14705. Epub 2017 Apr 25. No abstract available.

PMID:
28439879
37.

Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.

Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S, Buerkle C, Borchmann S, Fuchs M, Borchmann P, Diehl V, Engert A.

J Clin Oncol. 2017 Jun 20;35(18):1999-2007. doi: 10.1200/JCO.2016.70.9410. Epub 2017 Apr 18.

PMID:
28418763
38.

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE.

Ann Oncol. 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097. Review.

39.

Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors.

Baues C, Trommer-Nestler M, Jablonska K, Bröckelmann PJ, Schlaak M, von Bergwelt-Baildon M, Engert A, Semrau R, Marnitz S, Theurich S.

Immunotherapy. 2017 Mar;9(5):423-433. doi: 10.2217/imt-2017-0002. Review.

PMID:
28357914
40.

Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma.

Bröckelmann PJ, Müller H, Casasnovas O, Hutchings M, von Tresckow B, Jürgens M, McCall SJ, Morschhauser F, Fuchs M, Borchmann P, Moskowitz CH, Engert A.

Ann Oncol. 2017 Jun 1;28(6):1352-1358. doi: 10.1093/annonc/mdx072.

PMID:
28327958
41.

Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials.

Bröckelmann PJ, Goergen H, Kohnhorst C, von Tresckow B, Moccia A, Markova J, Meissner J, Kerkhoff A, Ludwig WD, Fuchs M, Borchmann P, Engert A.

J Clin Oncol. 2017 May 1;35(13):1444-1450. doi: 10.1200/JCO.2016.71.3289. Epub 2017 Feb 27.

PMID:
28240973
42.

Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.

Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A.

Lancet Oncol. 2017 Apr;18(4):454-463. doi: 10.1016/S1470-2045(17)30103-1. Epub 2017 Feb 22.

PMID:
28236583
43.

Sublethal pesticide doses negatively affect survival and the cellular responses in American foulbrood-infected honeybee larvae.

López JH, Krainer S, Engert A, Schuehly W, Riessberger-Gallé U, Crailsheim K.

Sci Rep. 2017 Feb 1;7:40853. doi: 10.1038/srep40853.

44.

Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci.

Law PJ, Sud A, Mitchell JS, Henrion M, Orlando G, Lenive O, Broderick P, Speedy HE, Johnson DC, Kaiser M, Weinhold N, Cooke R, Sunter NJ, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Carmichael J, Bailey JR, Pratt G, Rahman T, Pepper C, Fegan C, von Strandmann EP, Engert A, Försti A, Chen B, Filho MI, Thomsen H, Hoffmann P, Noethen MM, Eisele L, Jöckel KH, Allan JM, Swerdlow AJ, Goldschmidt H, Catovsky D, Morgan GJ, Hemminki K, Houlston RS.

Sci Rep. 2017 Jan 23;7:41071. doi: 10.1038/srep41071.

45.

Reply to H.J.A. Adams et al, E.A. Hawkes et al, and C.F. Hess et al.

Borchmann P, Engert A.

J Clin Oncol. 2017 Jan 20;35(3):375-376. doi: 10.1200/JCO.2016.69.7987. Epub 2016 Oct 28. No abstract available.

PMID:
28095272
46.

Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration.

Behringer K, Goergen H, Müller H, Thielen I, Brillant C, Kreissl S, Halbsguth TV, Meissner J, Greil R, Moosmann P, Shonukan O, Rueffer JU, Flechtner HH, Fuchs M, Diehl V, Engert A, Borchmann P.

J Clin Oncol. 2016 Dec 20;34(36):4329-4337. Epub 2016 Oct 31.

PMID:
27998235
47.

The emerging role of immune checkpoint inhibition in malignant lymphoma.

Hude I, Sasse S, Engert A, Bröckelmann PJ.

Haematologica. 2017 Jan;102(1):30-42. doi: 10.3324/haematol.2016.150656. Epub 2016 Nov 24. Review.

48.

Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma : New study concepts of the German Hodgkin Study Group.

Baues C, Semrau R, Gaipl US, Bröckelmann PJ, Rosenbrock J, Engert A, Marnitz S.

Strahlenther Onkol. 2017 Feb;193(2):95-99. doi: 10.1007/s00066-016-1050-4. Epub 2016 Oct 4.

PMID:
27704149
49.

New quality assurance program integrating "modern radiotherapy" within the German Hodgkin Study Group.

Kriz J, Baues C, Engenhart-Cabillic R, Haverkamp U, Herfarth K, Lukas P, Schmidberger H, Marnitz-Schulze S, Fuchs M, Engert A, Eich HT.

Strahlenther Onkol. 2017 Feb;193(2):100-108. doi: 10.1007/s00066-016-1048-y. Epub 2016 Sep 27.

PMID:
27678010
50.

Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group.

Kreissl S, Mueller H, Goergen H, Mayer A, Brillant C, Behringer K, Halbsguth TV, Hitz F, Soekler M, Shonukan O, Rueffer JU, Flechtner HH, Fuchs M, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group.

Lancet Oncol. 2016 Oct;17(10):1453-1462. doi: 10.1016/S1470-2045(16)30093-6. Epub 2016 Sep 6.

PMID:
27612583

Supplemental Content

Loading ...
Support Center